Caliper Technologies Corp. today announced that it has settled its patent infringement lawsuit against Molecular Devices Corp. The lawsuit alleged that Molecular Devices' "IMAP" assay products infringe Caliper's U.S. Patent Nos. 6,287,774 (the '774 patent) and 6,472,141 (the '141 patent). In connection with the settlement, Caliper and Molecular Devices have entered into a nonexclusive license agreement pursuant to which Molecular Devices has agreed to pay to Caliper a one-time licensing fee as well as royalties based on future sales of IMAP products. Financial details of the settlement were not disclosed.
The '774 and '141 patents cover methods and systems for performing a wide variety of assays in which the reaction product has a different charge than the substrate. The product (or substrate) is bound to a polyionic component, and the binding is detected by any of a variety of conventional methods, including fluorescence polarization. This method complements other microfluidic approaches, also developed by Caliper, to address important unmet needs in high-throughput pharmaceutical screening.
"We are pleased to have achieved this settlement. Now we can fully dedicate our efforts towards advancing our product pipeline and establishing greater market penetration in the life sciences and automation industries," says Kevin Hrusovsky, President and CEO of Caliper. "Additionally this settlement attests to the strength and value of our intellectual property estate and helps solidify our technology leadership in the area of high throughput screening, including the increasingly important area of kinase screening."
Today, Caliper has over 200 issued U.S. patents and a total portfolio of more than 600 pending and issued patents worldwide, covering microfluidic technology, instrumentation, applications, manufacturing technology, and related software.